First Wave BioPharma Inc
NASDAQ:ENTO
First Wave BioPharma Inc
NASDAQ:ENTO
Price:
2.85
USD
-5.32%
Market Cap:
$9.6m
Relative Value
There is not enough data to reliably calculate the relative value of ENTO.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ENTO
Relative Value
Base Case
Not Available
Multiples Across Competitors
ENTO Competitors Multiples
First Wave BioPharma Inc Competitors
First Wave BioPharma Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
First Wave BioPharma Inc
NASDAQ:ENTO
|
9.6m USD | 0 | -0.1 | -0.1 | -0.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
392.5B USD | 6.7 | 170.1 | 16.5 | 23.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.8B USD | 5.4 | 25.7 | 14.7 | 14.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
190.5B USD | 6.5 | 23.3 | 15.9 | 15.9 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.2B USD | 10.1 | 32.2 | 23.6 | 24.7 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.3B USD | 5.8 | 18.3 | 13.8 | 15.7 | |
| AU |
|
CSL Ltd
ASX:CSL
|
74.1B AUD | 3.3 | 17.2 | 11.8 | 14.7 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.2B EUR | 14.3 | 33.5 | 57.2 | 58.8 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
